About
Christian Hein
Independent executive advisor on artificial intelligence and digital transformation in healthcare. Based in Zurich. Working with life science leadership, techbio and healthtech founders, investors, and accelerator programs.
Background
Twenty years inside large pharma, most recently as Vice President for Digital Transformation at Novartis, before stepping out to advise full-time. Earlier in the trajectory: commercial strategy, market access, business development, regulatory, and innovation management across Switzerland, Germany, France, the United States, China, Russia, and the Middle East.
Educated at the École Supérieure de Biotechnologie de Strasbourg. Working languages: English, German, French.
What the advisory work covers
- AI strategy for life sciences executives, with emphasis on what actually compounds versus what is performative.
- Agentic transformation programs at the C-suite level, especially where the work meets a real P&L rather than a slide deck.
- Working with investors on due diligence, board roles, and strategic partnerships/go-to-market support for the portfolio.
- Bridging large pharma constraints with biotech and tech-bio ambition without losing what each side actually optimizes for.
Selected essays
A short starting shelf for the recurring arguments behind the advisory work.
- Isomorphic Labs at $50 Billion: A Bet on Human Data That Mostly Does Not Exist Yet — Isomorphic Labs raised $5 billion at a reported valuation of about $50 billion, with no drug in the clinic yet. I think that price holds only if Isomorphic solves the data problem in human biology.
- I said Anthropic would carry no drug asset. I was wrong — In IPO week, Anthropic disclosed a drug program it bought from Mithril Medicine, a one-person startup. Here is what that changes in my August prediction, and what still holds for pharma.
- Vertex's chairman calls AI cure timelines "complete BS" — Vertex's executive chairman called "complete BS" the claims that AI will cure most diseases within seven years. Ten years from now, I expect most human diseases will still be uncured.
- Anthropic's Frontier Academy: Palantir's FDE Model Meets SAP's Ecosystem Playbook — Anthropic wants 10,000 Frontier Deployed Engineers trained by the end of 2027 and has put $100 million behind it. I think it may be combining Palantir's FDE model with SAP's ecosystem economics.
- OpenEvidence exits Europe: what AI Act uncertainty means for clinical AI — OpenEvidence has withdrawn from the EU and UK citing regulatory uncertainty around the EU AI Act, making the geography of clinical AI access officially American. I break down what this means for US and European pharma, and why the AI Act's first observable market effect may be pushing physicians toward less-grounded AI alternatives.
- AI and CRO disruption: why IQVIA, Medpace, and Charles River may become more valuable — CRO stocks dropped sharply on AI fears: IQVIA, Medpace, Charles River. The market may be right that AI changes trial economics. It’s wrong about where the disruption lands. CROs are infrastructure companies, and AI should make them more valuable, not less — if they can break free from the cost-plus model.
Selected public references
A small set of public sources for current roles, governance work, interviews, and writing.
- SNOMED International — Management Board profile covering pharma leadership, health AI advisory work, and board appointment.
- QuantHealth — Advisory Board role with an AI-driven clinical trial simulation company.
- health.tech — Program Advisory Board profile for healthtech, AI, Novartis scaling work, SNOMED, QuantHealth, and Vorwerk Ventures.
- Kickstart Innovation — Community advisor profile for CH Health Tech Advisory.
- DayOne — Published advice for HealthTech startups on partnering with pharma, including AI scaling background.
- Healthcare IT News — Interview on why smaller health technology companies need partnerships to scale AI in healthcare.
- CH Health Tech Insights — Current writing on AI, pharma, healthtech, TechBio, governance, and adoption.
- LinkedIn — Current professional profile and ongoing public commentary.
Selected speaking and panels
A deliberately short set of public speaking references, focused on AI in healthcare and healthtech.
- Health Tech Forward — 2025 speaker profile for Health Tech Forward Barcelona, including HealthTech, AI, and venture advisory background.
- WHX Dubai — WHX in Dubai 2026 speaker profile in the official WHX Events app.
- World Health Expo Insights — Panel write-up and quoted commentary on generative AI in healthcare from WHX Tech-EHS Summit Dubai.
Press
- Handelsblatt — AI in pharma R&D and European AI strategy
- Swissinfo — Roche's AI supercomputer and pharma AI infrastructure
How to reach me
The fastest path is LinkedIn. For longer correspondence, read what I am writing first — most conversations start there.